Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Novartis
Nested Therapeutics, Inc
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
Eastern Cooperative Oncology Group
NRG Oncology
Institut Cancerologie de l'Ouest
Pfizer
Pfizer
UNICANCER
Bristol-Myers Squibb
Brigham and Women's Hospital
M.D. Anderson Cancer Center
Stanford University
Emory University
Hoffmann-La Roche
M.D. Anderson Cancer Center
Endeavor Biomedicines, Inc.
Neonc Technologies, Inc.
Children's Oncology Group
Essen Biotech
Essen Biotech
Sapience Therapeutics
St. Jude Children's Research Hospital
Melanoma Institute Australia
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Melanoma Institute Australia
Degron Therapeutics Co.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University of Utah
Yale University
Cancer Research UK
Cancer Research UK
Seattle Children's Hospital
Sutter Health
GlaxoSmithKline
UNC Lineberger Comprehensive Cancer Center
Pfizer
University of Arizona
Virginia Commonwealth University
Day One Biopharmaceuticals, Inc.
Hadassah Medical Organization